 LEXINGTON, Mass., Nov. 04, 2021 GLOBE NEWSWIRE -- Keros Therapeutics, Inc. Keros Nasdaq: KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that four abstracts will be presented from the KER-050 and ALK2 hematology programs, including additional preliminary results from Keros Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes MDS, at the 63rd American Society of Hematology ASH Annual Meeting and Exposition, to be held in person and virtually from December 11 through 14, 2021. 